BAMS
SUPN icon

Bellevue Asset Management (Switzerland)’s Supernus Pharmaceuticals SUPN Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$4.77M Buy
355,000
+35,000
+11% +$541K 0.73% 49
2015
Q3 		$4.49M Buy
+320,000
New +$5.95M 0.73% 50

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s SUPN Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) increased its Supernus Pharmaceuticals (SUPN) stake by 11% in Q4 2015, buying an estimated $541K and bringing the position to 355,000 shares worth $4.77M. The position accounts for 0.73% of the portfolio, ranked #49.

Bellevue Asset Management (Switzerland) first reported a position in SUPN in Q3 2015 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold SUPN as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 355,000 shares of Supernus Pharmaceuticals worth $4.77M as of Q4 2015.
  • Bellevue Asset Management (Switzerland) bought 35,000 Supernus Pharmaceuticals shares in Q4 2015, an estimated $541K.
  • Supernus Pharmaceuticals made up 0.73% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #49 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Supernus Pharmaceuticals in Q3 2015 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.